Clinical Trials Logo

Acute-On-Chronic Liver Failure clinical trials

View clinical trials related to Acute-On-Chronic Liver Failure.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03860155 Terminated - Clinical trials for Acute-On-Chronic Liver Failure

Allogeneic ABCB5-positive Stem Cells for Treatment of Acute-on-Chronic Liver Failure

Start date: March 22, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is an interventional, single arm, multicenter, phase I/IIa clinical trial. The study objective is to investigate the efficacy and safety of three i.v. doses of the investigational medicinal product (IMP) allo-APZ2-ACLF for the treatment of acute-on-chronic liver failure (ACLF). The allogeneic IMP allo-APZ2-ACLF contains skin-derived ABCB5-positive mesenchymal stem cells isolated from skin tissue of healthy donors and stored in a donor cell bank.

NCT ID: NCT02857010 Terminated - Clinical trials for Acute on Chronic Hepatic Failure

Allogenic Bone Marrow Mesenchymal Stem Cell Therapy in Acute-on-chronic Liver Failure

Liveradvance
Start date: February 2016
Phase: Phase 1
Study type: Interventional

Double-blind placebo randomized controlled trial evaluating the clinical efficacy of allogenic bone marrow derived mesenchymal stem cells in cirrhotic patients with acute-on-chronic liver failure

NCT ID: NCT02788240 Terminated - Clinical trials for Acute on Chronic Liver Failure

To Study the Influence of GCSF on Natural History of Acute On Chronic Liver Failure After the Acute Phase

Start date: May 1, 2016
Phase: N/A
Study type: Interventional

All consecutive ACLF (Acute on Chronic Liver failure) patients presenting to the institute of liver and biliary sciences, irrespective of the etiology , who have survived the acute phase (i.e. 90 days of onset of the acute on chronic liver failure) and who are willing to participate in the study would be enrolled. After performing baseline biochemical tests, patients will undergo transjugular liver biopsy (TJLB), HVPG (Hepatic Venous Pressure Gradient), Circulating CD34 cells, Bone marrow aspiration and biopsy (Histopathological and immunohistochemical examination will be done).

NCT ID: NCT01079091 Terminated - Clinical trials for Acute on Chronic Hepatic Failure

Hepa Wash Treatment of Patients With Acute-on-Chronic Liver Failure in Intensive Care Units

HEPATICUS-1
Start date: September 2010
Phase: N/A
Study type: Interventional

Patients with compensated chronic liver disease who have an episode of acute deterioration of liver function (acute-on-chronic liver failure) are known to have up to 90% mortality rate. Hepa Wash(R) is a newly developed liver and renal support system that is based on the use of recycled albumin dialysate. The new system has shown a high detoxification capacity in in-vitro and preclinical studies. The aim of the study is to evaluate the safety and efficacy of the Hepa Wash system in patients with acute-on-chronic liver failure in the intensive care unit.